The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 23990988.
- Also identified by DOI 10.1371/journal.pone.0071785 and PMC identifier 3747197.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
BACKGROUND: Growing studies have revealed the association between polymorphisms in the Toll-like receptor 9 (TLR9) and susceptibility to cancer, however, the results remained inconsistent. METHODOLOGY/PRINCIPAL FINDINGS: To assess the effect of three selected SNPs (rs352140, rs5743836 and rs187084) in TLR9 on cancer, we performed a meta-analysis based on 11 case-control studies, including a total of 6,585 cancer cases and 7,506 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) for polymorphisms in TLR9 and cancer risk were estimated. Our meta-analysis indicated that rs352140 was associated with an increased cancer risk, especially in Caucasian. However, no significantly increased cancer risk was detected to be associated with rs187084 and rs5743836 either the overall or subgroup estimation. CONCLUSIONS: These meta-analysis results indicate that polymorphisms in TLR9 may play a role in cancer development.
Medical subject headings
- Genetic Predisposition to Disease
- Neoplasms
- Polymorphism, Single Nucleotide
- Toll-Like Receptor 9